Data / Federal awards / NAICS 541711 / EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.
EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.: 7 federal contract awards, $474.8 million obligated (FY2024 to FY2027)
Updated October 6, 2026. Source: USAspending.gov.
EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (UEI CNPVCR8DK7M8), Gaithersburg, MD, received 7 federal prime contract awards with $474.8 million obligated in fiscal years 2024 to 2027, from 2 agencies under 4 NAICS codes. Its largest buyer is Department of Health and Human Services ($475.9 million) and its largest code is NAICS 541711 Research and Development in Biotechnology.
The request: Every federal contract awarded under NAICS 541711, with the winner, the agency and the value. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every federal contract award on USAspending.gov and every open opportunity on SAM.gov, and this page is that reading. Ask for the awards in your niche and the winners, agencies, values and recompetes arrive in your sheet, CRM, Slack or agent as they are reported.
- UEI
- CNPVCR8DK7M8
- Parent organization
- EMERGENT BIOSOLUTIONS INC
- Location
- Gaithersburg, MD
- Business size
- Other Than Small Business
- Contract awards
- 7
- Obligated
- $474.8 million
- First action in window
- 2023-10-06
- Latest action
- 2026-08-18
Where the work is
NAICS codes, with the other winners in each.
| NAICS | Industry | Awards | Obligated |
|---|---|---|---|
| 541711 | Research and Development in Biotechnology | 3 | $208.8 million |
| 325414 | Biological Product (except Diagnostic) Manufacturing | 1 | $208.5 million |
| 541714 | Research and Development in Biotechnology (except Nanobiotechnology) | 2 | $58.6 million |
| 541715 | Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) | 1 | $-1,138,106 |
Buying agencies
| Agency | Awards | Obligated |
|---|---|---|
| Department of Health and Human Services | 6 | $475.9 million |
| Department of Defense | 1 | $-1,138,106 |
Obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2024 | $245.6 million |
| FY2025 | $152.4 million |
| FY2026 | $76.8 million |
Contract awards
All 7 awards in fiscal years 2024 to 2027.
| Award ID | Agency | Type | NAICS | What it buys | Obligated in window | Award value | Starts | Ends | Place of performance | Source |
|---|---|---|---|---|---|---|---|---|---|---|
| HHSO100201600030C | Department of Health and Human Services | Definitive Contract | 541711 | IGF::OT::IGF | $208,983,524 | $1,409,725,727 | September 30, 2016 | September 29, 2026 | Gaithersburg, MD | usaspending.gov |
| 75A50119C00071 | Department of Health and Human Services | Definitive Contract | 325414 | ACAM2000, SMALLPOX (VACCINIA) VACCINE, LIVE (ACAM) | $208,483,581 | $857,637,641 | August 30, 2019 | September 30, 2026 | Gaithersburg, MD | usaspending.gov |
| 75A50123C00037 | Department of Health and Human Services | Definitive Contract | 541714 | MEDICAL COUNTERMEASURES (MCM) THAT CAN BE DEPLOYED IN THE EVENT OF A FILOVIRUS OUTBREAK ARE A CRUCIAL COMPONENT TO THE UNITED STATES GOVERNM | $58,589,653 | $237,127,358 | July 31, 2023 | July 29, 2033 | Gaithersburg, MD | usaspending.gov |
| 75N98026P00379 | Department of Health and Human Services | Purchase Order | 541714 | HIV BIOLOGICS MASTER FILE SUPPORT POP: 4/27/26 TO 3/31/27, EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG, INC. | $11,232 | $11,232 | April 27, 2026 | March 31, 2027 | Rockville, MD | usaspending.gov |
| HHSO100201700001C | Department of Health and Human Services | Definitive Contract | 541711 | IGF::OT::IGF - ADVANCING STABILIZED ISOAMYL NITRITE FOR INTRANASAL TREATMENT OF CYANIDE EXPOSURE | $0 | $32,952,759 | September 15, 2017 | June 3, 2024 | Gaithersburg, MD | usaspending.gov |
| HHSO100201500004C | Department of Health and Human Services | Definitive Contract | 541711 | IGF::OT::IGF FOR OTHER FUNCTIONSTHIS CONTRACT IS FOR THE ADVANCED DEVELOPMENT OF NUTHRAX (ANTHRAX VACCINE ABSORBED WITH CPG 7909) OR AV7909 | $-147,973 | $43,794,113 | March 23, 2015 | July 31, 2019 | Gaithersburg, MD | usaspending.gov |
| W81XWH19C0193 | Department of Defense | Definitive Contract | 541715 | CREATION OF AN FDA APPROVED ANALGESIC KETAMINE DRUG WITH AUTO INJECTOR DELIVERY SYSTEM. | $-1,138,106 | $5,721,771 | September 26, 2019 | February 29, 2024 | Gaithersburg, MD | usaspending.gov |
Also on SpecStream
- All recipients under NAICS 541711 Research and Development in Biotechnology
- All recipients under NAICS 325414 Biological Product (except Diagnostic) Manufacturing
- All recipients under NAICS 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Open opportunities under NAICS 325414
- Open opportunities under NAICS 541714
Public U.S. federal spending data (U.S. Department of the Treasury). Obligations are the contract actions dated in fiscal years 2024 to 2027 of the USAspending.gov award archive of 2026-10-06; a contract's total value is its current value as USAspending reports it, including earlier years. Recipients are matched on their SAM.gov UEI, never on the name, and are shown as the government prints them. Sole proprietorships and opted-out entities count in the totals and are not named. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.